VISEN Pharmaceuticals

VISEN Pharmaceuticals VISEN Pharmaceuticals VISEN Pharmaceuticals
  • HOME
  • COMPANY
    全部 OVERVIEW VALUE BOARD OF DIRECTORS CONTACT
  • PIPELINE
    全部 TransConTM hGH TransConTM PTH TransConTM CNP
  • PATIENTS
    全部 GROWTH HORMONE DEFICIENCY HYPOPARATHYROIDISM ACHONDROPLASIA
  • CAREERS
    全部 COMPANY CULTURE JOB OPPORTUNITIES
  • MEDIA
    全部 PRESS RELEASE
  • 中

  • INNOVATION

    Committed to bring innovative medications to the Greater China

  • COLLABORATION

    Close collaboration with local government,research institutes and medical societies to provide medical solution to unmet clinical needs

  • EFFECTIVENESS

    To rapidly commercialize targeted new drugs and medications under challenging regulatory environment and market access

TransConTM TECHNOLOGY

  • PROPRIETARY<br>TECHNOLOGY

    ▼Parent drug is transiently bound to linker-carrier, which inactivates and shields it from clearance
    ▼Following injection, the linker is designed to auto-hydrolyze at specific rates to predictably release unmodified parent drug
    ▼Designed to distribute parent drug compound like the endogenous compound; linker-carrier is cleared renally

  • EFFICACY

    ▼Predictable release of unmodified parent drug supporting dosing frequency from daily to up to six months or more
    ▼Enables sustained localized or systemic drug exposure
    ▼Reduces dosing frequency to improve patient adherence and improve overall treatment outcomes

  • SAFETY

    ▼Same mode of action as parent drug
    ▼Same established safety profile as parent drug with potential enhancements or improvements due to application of TransCon technologies
    ▼Enables comparable alternative to continuous infusions or subcutaneous injections

  • INTELLECTUAL PROPERTY

    ▼Patent for invention(New composition of matter patents)
    ▼Exclusive license to develop and commercialize Ascendis Pharma’s endocrinology therapies in Greater China

MEDIA

2021-03/30
VISEN’s TransConTM Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Schedule

(March 30th, 2021, Shanghai, China) VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, announced today that it had successfully completed its recruitin

2021-01/09
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China

VISEN Pharmaceuticals Closes $150 Million Series B Financing Today

VIEW MORE

COMPANY

  • OVERVIEW
  • VALUE
  • BOARD OF DIRECTORS
  • CONTACT

PIPELINE

  • TransConTM hGH
  • TransConTM PTH
  • TransConTM CNP

PATIENTS

  • GROWTH HORMONE DEFICIENCY
  • HYPOPARATHYROIDISM
  • ACHONDROPLASIA

CAREERS

  • COMPANY CULTURE
  • JOB OPPORTUNITIES

This webpage is not a commercial advertisement. Only for healthcare professionals to read and reference.
Copyright VISEN Pharma (Shanghai) Co., Ltd    沪ICP备19045055